NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. [PDF]
JCO Precis Oncol, 2021 PURPOSE Neurotrophic tyrosine receptor kinase (NTRK) fusions have been described as oncogenic drivers in a variety of tumors. However, little is known about the overall frequency of NTRK fusion in unselected pediatric tumors.
Zhao X +18 more
europepmc +4 more sources
A review of NTRK fusions in cancer. [PDF]
Ann Med Surg (Lond), 2022 The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3.
Manea CA +9 more
europepmc +4 more sources
NTRK fusions are extremely rare in bone tumours. [PDF]
Histopathology, 2021 Because of the efficacy of tropomyosin receptor kinase (Trk) inhibitor therapy in tumours with rearrangements of the neurotrophic tyrosine kinase receptor genes (NRTK genes), there has been a surge in demand for NTRK fusion screening.
Lam SW +6 more
europepmc +7 more sources
NTRK fusions in lung cancer: From biology to therapy. [PDF]
Lung Cancer, 2021 Fusions involving TRK protein tyrosine kinases are oncogenic drivers in a variety of tumors in children and adults, with a prevalence of ∼0.2% in non-small cell lung cancer. Diagnosis can be challenging due to structural features such as NTRK intron length, but next-generation sequencing (NGS), including RNA-based NGS, increases detection.
Harada G +3 more
europepmc +4 more sources
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [PDF]
npj Precision Oncology, 2021 Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence
C. B. Westphalen +11 more
doaj +2 more sources
Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. [PDF]
Mol Diagn Ther, 2023 Introduction Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions occur in ~ 0.3% of all solid tumours but are enriched in some rare tumour types.
Silvertown JD +14 more
europepmc +2 more sources
NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma [PDF]
Frontiers in Oncology, 2020 IntroductionGlioblastoma multiforme (GBM) is the most common primary central nervous (CNS) system malignancy with a poor prognosis. The standard treatment for GBM is neurosurgical resection, followed by radiochemotherapy and adjuvant temozolomide ...
Yuekun Wang +3 more
doaj +2 more sources
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research [PDF]
Annals of Oncology, 2019 Background NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine kinases, and biomarkers for the use ...
A.J. Iafrate +11 more
core +3 more sources
NTRK fusions in osteosarcoma are rare and non‐functional events [PDF]
The Journal of Pathology: Clinical Research, 2020 Neurotrophic tyrosine receptor kinase (NTRK) fusions are promising molecular targets that have been described in a broad range of malignant tumours. Fusions commonly lead to the expression of chimeric proteins with constitutive tyrosine kinase activation
Baptiste Ameline +8 more
doaj +2 more sources
Evaluation of <i>NTRK</i> Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma. [PDF]
Int J Mol SciNeurotrophic tyrosine receptor kinase (NTRK) fusions function as oncogenes and have been targeted by TRK inhibitors with excellent clinical outcomes.
Momma T +14 more
europepmc +2 more sources